Standards affecting the consistency of gene expression arrays in clinical applications.

ABSTRACT

The use of microarray technology to measure gene expression has created optimism for the feasibility of using molecular assessments of tumors routinely in the clinical management of cancer. Gene expression arrays have been pioneers in the development of standards; both for research use and now for clinical application. Some of the existing standards have been driven by the early perception that microarray technology was inconsistent and perhaps unreliable. More recent experimentation has shown that reproducible data can be achieved and clinical standards are beginning to emerge. For the transcriptional assessment of tumors, this means a system that correctly samples a tumor, isolates RNA and processes this for microarray analysis, evaluates the data, and communicates findings in a consistent and timely fashion. The most important standard is to show that a clinically important assessment can be made with microarray data. The standards emerging from work on various parts of the entire process could guide the development of a workable system. However, the final standard for each component of the process depends on the accuracy required when the assay becomes part of the clinical routine a routine that now includes the molecular evaluation of tumors.